| Previous Close | 21.19 |
| Open | 21.19 |
| Day High | 21.65 |
| Day Low | 20.2 |
| 52-Week High | 33.63 |
| 52-Week Low | 13.8 |
| Volume | 21,130 |
| Average Volume | 58,135 |
| Market Cap | 38.7M |
| PE | -83.27 |
| EPS | -0.26 |
| Moving Average 50 Days | 23.5 |
| Moving Average 200 Days | 24.35 |
| Change | 0.46 |
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
GlobeNewswire Inc.
Mar 10, 2026 1:00 PM GMT
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRP
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
GlobeNewswire Inc.
Feb 25, 2026 2:30 PM GMT
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1MNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (u
Precipio Takes Major Steps Toward a Clean Balance Sheet
GlobeNewswire Inc.
Jan 15, 2026 2:00 PM GMT
Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstandingNEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has made major strides in cleaning up its balan